W. Fraser Symmans

The University of Texas MD Anderson Cancer Center

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 1%percentile

7.4Author DataRank

Indexed papers

6in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 6 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies

Cancer Cell(2022)10.1016/j.ccell.2022.05.005

Top 4%

4.9DataRank

Top 4%329 citations

Christina Yau, Julia Wulfkuhle, Lamorna Brown Swigart, Rosa I. Gallagher, Pei Rong Evelyn Lee +28 more

Papers

Driven by 58 papers — median percentile 0. Top paper: “Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer”.

Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer

JAMA Oncology(2020)10.1001/jamaoncol.2020.2535

N/A

6.3DataRank · unranked

225 citations

Angela DeMichele, Christina Yau, Claudine Isaacs, W. Fraser Symmans, Kathy S. Albain +74 more

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies

Cancer Cell(2022)10.1016/j.ccell.2022.05.005

Top 4%

4.9DataRank

Top 4%329 citations

Christina Yau, Julia Wulfkuhle, Lamorna Brown Swigart, Rosa I. Gallagher, Pei Rong Evelyn Lee +28 more

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

npj Breast Cancer(2021)10.1038/s41523-021-00346-1

N/A

4.9DataRank · unranked

281 citations

Harry R. Haynes, Elizabeth F. Blackley, Susan Fineberg, Jeffrey Shear, Sophia Turner +73 more

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group

npj Breast Cancer(2020)10.1038/s41523-020-0154-2

N/A

3.5DataRank · unranked

168 citations

Elisabeth Specht Stovgaard, Eva Balslev, Jeppe Thagaard, Weijie Chen, Sarah Dudgeon +95 more

Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis

Nature Cancer(2022)10.1038/s43018-022-00491-x

Top 9%

2.4DataRank

Top 9%114 citations

Toshinori Hinoue, Gregory Wheeler, Benjamin Kelly, Ana C. Garrido-Castro, Tomás Pascual +53 more

Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0144

N/A

2.0DataRank · unranked

79 citations

Er-Yen Yen, Jeffrey T. Chang, Roland L. Bassett, Gheath Alatrash, Haven R. Garber +26 more

Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Nature Medicine(2024)10.1038/s41591-024-03267-1

N/A

1.4DataRank · unranked

43 citations

Meghna S. Trivedi, Christina Yau, Rita Nanda, Hope S. Rugo, Marie Davidian +55 more

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

The Lancet Oncology(2021)10.1016/s1470-2045(21)00589-1

N/A

0.917DataRank · unranked

451 citations

Marie Osdoit, Marieke van der Noordaa, Sonal Shad, Jane Wei, Diane de Croze +94 more

Alliance A011801 (compassHER2 RD): Postneoadjuvant T-DM1 + Tucatinib/Placebo in Patients with Residual HER2-Positive Invasive Breast Cancer

Future Oncology(2021)10.2217/fon-2021-0753

N/A

0.901DataRank · unranked

30 citations

Karla V. Ballman, Linda McCall, Anuhya Kommalapati, Tyler Zemla, Anna Weiss +12 more

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer

npj Breast Cancer(2022)10.1038/s41523-022-00493-z

N/A

0.900DataRank · unranked

27 citations

Andres Forero‐Torres, Douglas Yee, Christina Yau, Denise M. Wolf, John Park +44 more

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

Cancer Cell(2021)10.1016/j.ccell.2021.05.009

N/A

0.873DataRank · unranked

337 citations

Christina Yau, Denise M. Wolf, Hyo S. Han, Lili Du, Anne M. Wallace +40 more

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

npj Breast Cancer(2020)10.1038/s41523-020-0156-0

N/A

0.801DataRank · unranked

208 citations

Elvire Roblin, Rim S. Kim, Stefan Michiels, Brandon D. Gallas, Weijie Chen +95 more

Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy

Cancer Cell(2023)10.1016/j.ccell.2023.04.008

N/A

0.777DataRank · unranked

177 citations

Lamorna Brown Swigart, Ziad Ahmed, Rosalyn W. Sayaman, Derrick Renner, Ekaterina Kalashnikova +26 more

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

Nature Communications(2021)10.1038/s41467-021-26019-y

N/A

0.648DataRank · unranked

74 citations

Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, L. J. van ‘t Veer, Douglas Yee +46 more

Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Nature Medicine(2024)10.1038/s41591-024-03266-2

N/A

0.610DataRank · unranked

13 citations

Jane Meisel, Christina Yau, Hope S. Rugo, Rita Nanda, Marie Davidian +52 more

Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

Cancer Research(2023)10.1158/0008-5472.can-23-1711

N/A

0.596DataRank · unranked

15 citations

Yingtian Xie, Shira Sherman, Zsuzsanna Nagy, Douglas Russo, Tara Akhshi +36 more

Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy

Annals of Oncology(2021)10.1016/j.annonc.2021.02.011

N/A

0.574DataRank · unranked

45 citations

Christina Yau, Lamorna Brown Swigart, Rebekah Gould, Gregor Krings, Gillian L. Hirst +27 more

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

npj Breast Cancer(2021)10.1038/s41523-021-00337-2

N/A

0.510DataRank · unranked

29 citations

Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar +50 more

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2256

N/A

0.457DataRank · unranked

20 citations

Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien +44 more

Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial

Cell Reports Medicine(2023)10.1016/j.xcrm.2023.101312

N/A

0.442DataRank · unranked

18 citations

Julia Wulfkuhle, Denise M. Wolf, Lamorna Brown Swigart, Christina Yau, Nicholas O’Grady +22 more

Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials

Nature Communications(2023)10.1038/s41467-023-42635-2

N/A

0.434DataRank · unranked

17 citations

Aranzazu Fernández-Martínez, David Venet, Françoise Rothé, Katherine A. Hoadley, Joel S. Parker +17 more

Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502

npj Breast Cancer(2024)10.1038/s41523-024-00683-x

N/A

0.419DataRank · unranked

7 citations

Roberto Salgado, Oleksander Savenkov, Karla V. Ballman, Erica L. Mayer, Mark Jesus M. Magbanua +11 more

Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2928

N/A

0.406DataRank · unranked

14 citations

Ziad Ahmed, Rosalyn W. Sayaman, Lamorna Brown Swigart, Gillian L. Hirst, Christina Yau +13 more

Adjuvant Dose-Dense Chemotherapy in Hormone Receptor–Positive Breast Cancer

Journal of Clinical Oncology(2025)10.1200/jco-24-01875

N/A

0.319DataRank · unranked

6 citations

Karla V. Ballman, Jordan D. Campbell, Minetta C. Liu, Jennifer A. Ligibel, Mark A. Watson +12 more

Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy

Investigational New Drugs(2023)10.1007/s10637-023-01357-4

N/A

0.285DataRank · unranked

5 citations

Ryan Sun, Roland L. Bassett, Lei Huo, Jeffrey T. Chang, Mediget Teshome +24 more

Stain SAN: simultaneous augmentation and normalization for histopathology images

Journal of Medical Imaging(2024)10.1117/1.jmi.11.4.044006

N/A

0.269DataRank · unranked

5 citations

Yao Li, Benjamin C. Calhoun, Aatish Thennavan, Lisa A. Carey, W. Fraser Symmans +4 more

Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer

Breast Cancer Research and Treatment(2024)10.1007/s10549-024-07555-9

N/A

0.255DataRank · unranked

4 citations

Mike Campbell, Christina Yau, A. Jo Chien, Anne M. Wallace, Claudine Isaacs +18 more

Reply to T. Shimoi et al and Y. Shimanuki et al

Journal of Clinical Oncology(2021)10.1200/jco.21.01905

N/A

0.209DataRank · unranked

2 citations

Fengmin Zhao, Carlos L. Arteaga, W. Fraser Symmans, Ben Ho Park, Brian L. Burnette +20 more

Adjuvant platinum versus capecitabine for residual, invasive, triple‐negative breast cancer: Patient‐reported outcomes in ECOG‐ACRIN EA1131

Cancer(2024)10.1002/cncr.35187

N/A

0.208DataRank · unranked

3 citations

Fengmin Zhao, Ingrid A. Mayer, Amyé Tevaarwerk, Sofia F. Garcia, Carlos L. Arteaga +20 more

Association of tumor infiltrating lymphocyte quantity with survival in patients (pts) with metastatic breast cancer (MBC) receiving microtubule-targeting agents: Post hoc analysis CALGB 40502 (Alliance).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.1010

N/A

0.203DataRank · unranked

2 citations

Roberto Salgado, Oleksandr Savenkov, Karla V. Ballman, Mark Jesus M. Magbanua, Sherene Loi +11 more

Multiplatform Analysis of Primary and Metastatic Breast Tumors from the AURORA US Network identifies microenvironment and epigenetics drivers of metastasis

Research Square(2022)10.21203/rs.3.rs-1221704/v1

N/A

0.165DataRank · unranked

2 citations

Susana García‐Recio, Toshinori Hinoue4, Gregory Wheeler, Benjamin Kelly, Ana C. Garrido-Castro +49 more

Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.514

N/A

0.104DataRank · unranked

1 citations

Denise M. Wolf, Christina Yau, Emanuel F. Petricoin, Paula R. Pohlmann, Lajos Pusztai +10 more

Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial

Annals of Surgical Oncology(2025)10.1245/s10434-025-17864-y

N/A

0.104DataRank · unranked

1 citations

Katrina Dimitroff, Judy C. Boughey, Laura J. Esserman, Christina Yau, Julia Tchou +34 more

Pre‐analytical effects on whole transcriptome and targeted RNA sequencing analysis in cytology: The effects of prolonged time in storage of effusion specimens prior to preservation

Cytopathology(2023)10.1111/cyt.13304

N/A

0DataRank · unranked

5 citations

Kevin Tran, Chunxiao Fu, Lili Du, Michal Marczyk, Rebekah Gould +5 more

Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer

npj Breast Cancer(2023)10.1038/s41523-022-00502-1

N/A

0DataRank · unranked

23 citations

Shirong Cai, Yizheng Tu, Jiansu Shao, Emily Powell, Abena B. Redwood +22 more

Network Modeling of Complex Time-Dependent Changes in Patient Adherence to Adjuvant Endocrine Treatment in ER+ Breast Cancer

Frontiers in Psychology(2022)10.3389/fpsyg.2022.856813

N/A

0DataRank · unranked

0 citations

Brooke E. Busch, Neda Jasemi, Cole A. Lyman, J. Tory Toole, Spencer Richman +5 more

Distribution of breast cancer molecular subtypes within receptor classifications: Lessons from the I-SPY2 Trial and FLEX Registry.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.592

N/A

0DataRank · unranked

1 citations

Paige Warner, Robert Hiatt, Scarlett Lin Gomez, L. J. van ‘t Veer, Allison Stover Fiscalini +11 more

Data from Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031)

(2023)10.1158/1078-0432.c.6532350

Top 100%

0DataRank

Top 100%0 citations

Lili Du, Tanya L. Hoskin, Meenakshi Anurag, X. Cynthia, Isabelle Bedrosian +4 more

Data from Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031)

(2023)10.1158/1078-0432.c.6532350.v1

Top 100%

0DataRank

Top 100%0 citations

Lili Du, Tanya L. Hoskin, Meenakshi Anurag, X. Cynthia, Isabelle Bedrosian +4 more

Data from An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

(2023)10.1158/0008-5472.c.6497325

Top 100%

0DataRank

Top 100%0 citations

Ana M. González-Angulo, Aňa Lluch, Richard M. Neve, Wen-lin Kuo, Michael A. Davies +17 more

Data from Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer

(2023)10.1158/1078-0432.c.6530597

N/A

0DataRank · unranked

0 citations

Er-Yen Yen, Jeffrey T. Chang, Roland L. Bassett, Gheath Alatrash, Haven R. Garber +26 more

Data from Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer

(2023)10.1158/1078-0432.c.6530597.v1

N/A

0DataRank · unranked

0 citations

Er-Yen Yen, Jeffrey T. Chang, Roland L. Bassett, Gheath Alatrash, Haven R. Garber +26 more

Reply to Y. Wang et al and Q. Sui et al

Journal of Clinical Oncology(2023)10.1200/jco.23.00722

N/A

0DataRank · unranked

0 citations

William E. Barlow, W. Fraser Symmans, Corey Speers

Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials

Annals of Oncology(2022)10.1016/j.annonc.2022.04.072

N/A

0DataRank · unranked

21 citations

Anna Mrukwa, Christina Yau, Denise M. Wolf, Y.-Y. Chen, Ronald Balassanian +26 more

Molecular testing opportunities on cytology effusion specimens: the pre-analytic effects of various body fluid cytology preparation methods on RNA extraction quality and targeted sequencing

Journal of the American Society of Cytopathology(2022)10.1016/j.jasc.2022.09.003

N/A

0DataRank · unranked

12 citations

Kevin Tran, Chunxiao Fu, Lili Du, Michal Marczyk, Yadira Alatriste Martínez +5 more

Evaluation of sensitivity to endocrine therapy index (SET2,3) for response to neoadjuvant endocrine therapy (NET) and subsequent prognosis.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.580

N/A

0DataRank · unranked

0 citations

Lili Du, Tanya L. Hoskin, Meenakshi Anurag, X. Cynthia, Isabelle Bedrosian +4 more

Acquisition of cancer stem cell properties during EMT requires cell division

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.07.01.449976

N/A

0DataRank · unranked

6 citations

Suhas Vasaikar, María Castañeda, Robiya Joseph, Abhijeet Deshmukh, Tieling Zhou +6 more

A randomized phase III post-operative trial of platinum-based chemotherapy (P) versus capecitabine (C) in patients (pts) with residual triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy (NAC): ECOG-ACRIN EA1131

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.605

N/A

0DataRank · unranked

7 citations

Fengmin Zhao, Carlos L. Arteaga, W. Fraser Symmans, Ben Ho Park, Brian L. Burnette +12 more

Targeted RNAseq assay incorporating unique molecular identifiers for improved quantification of gene expression signatures and transcribed mutation fraction in fixed tumor samples

BMC Cancer(2021)10.1186/s12885-021-07814-8

N/A

0DataRank · unranked

10 citations

Michal Marczyk, Michael L. Samuels, Alexander J. Trevarton, Jiaxin Qu, Rosanna Lau +8 more

A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer

Investigational New Drugs(2020)10.1007/s10637-020-00995-2

N/A

0DataRank · unranked

28 citations

Gaiane M. Rauch, Tanbin Rahman, Meghan Karuturi, Elizabeth E. Ravenberg, Jason B. White +14 more

Comparative analysis of Ficoll-Hypaque and CytoLyt techniques for blood removal in breast cancer malignant effusions: effects on RNA quality and sequencing outcomes

Journal of the American Society of Cytopathology(2024)10.1016/j.jasc.2024.11.001

N/A

0DataRank · unranked

2 citations

Kevin Tran, Alexander J. Trevarton, Michal Marczyk, Chunxiao Fu, Lili Du +10 more

Challenges and Gaps in Clinical Trial Genomic Data Management

UNC Libraries(2024)10.17615/kaqf-dw34

Top 100%

0DataRank

Top 100%0 citations

Kurt R. Mueller, Samina Asad, Daniel G. Stover, Charles M. Perou, Yujia Wen +5 more

Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancer

Scientific Reports(2020)10.1038/s41598-020-74882-4

N/A

0DataRank · unranked

22 citations

Abena B. Redwood, Xuan Liu, Lei Guo, Shirong Cai, Xinhui Zhou +19 more

Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapy

Communications Medicine(2025)10.1038/s43856-024-00728-z

N/A

0DataRank · unranked

6 citations

Heinz‐Josef Lenz, Gianluigi Pillonetto, Raúl Méndez-Giráldez, Hanna K. Sanoff, Reza Hadi +17 more

Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapy

UNC Libraries(2025)10.17615/rbz3-7m15

N/A

0DataRank · unranked

0 citations

Scott Kopetz, Rashid, Naim U, Mark J. Ratain, Esmat Samiei, Federico Innocenti +18 more

Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer

medRxiv(2025)10.1101/2025.08.25.25334393

N/A

0DataRank · unranked

0 citations

James M. Dolezal, Hanna M. Hieromnimon, Sara J. Venters, Sara Kochanny, Anran Li +31 more

EMT-induced stem cell and mesenchymal programs can be decoupled via cell division and ESRP1-dependent mechanisms

iScience(2025)10.1016/j.isci.2025.114284

N/A

0DataRank · unranked

0 citations

María Castañeda, Suhas Vasaikar, Joanna Joyce Maddela, Claire Gould, Breanna R. Demestichas +17 more

Assessment of stained direct cytology smears of breast cancer for whole transcriptome and targeted messenger RNA sequencing

Cancer Cytopathology(2023)10.1002/cncy.22679

N/A

0DataRank · unranked

9 citations

Chunxiao Fu, Rosanna Lau, Lili Du, Alexander J. Trevarton, Bruno V. Sinn +5 more

W. Fraser Symmans

Indexed papers

Top data-sharing exemplar

Papers